利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

138 条记录 (耗时 0.101 秒)

    GENETIC MARKERS FOR RISK MANAGEMENT OF VASCULAR DISEASE
    54.
    发明申请
    GENETIC MARKERS FOR RISK MANAGEMENT OF VASCULAR DISEASE 审中-公开
    血管疾病风险管理遗传标记

    公开(公告)号：US20130224739A1

    公开(公告)日：2013-08-29

    申请号：US13806045

    申请日：2011-06-22

    申请人： Gudmar Thorleifsson ,  Solveig Gretarsdottir

    发明人： Gudmar Thorleifsson ,  Solveig Gretarsdottir

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6883 ,  C12Q2600/118 ,  C12Q2600/156

    摘要： Certain genetic markers have been found to be useful for risk management of vascular conditions, including abdominal aortic aneurysm, myocardial infarction, peripheral arterial disease and venous thromboembolism. The invention provides diagnostic applications using such markers, including methods of determining a susceptibility of vascular conditions.

    摘要翻译： 已经发现某些遗传标记可用于血管病变的风险管理，包括腹主动脉瘤，心肌梗死，外周动脉疾病和静脉血栓栓塞。 本发明提供了使用这种标记的诊断应用，包括确定血管病变易感性的方法。

    Genetic variants as markers for use in diagnosis, prognosis and treatment of eosinophilia, asthma, and myocardial infarction
    55.
    发明授权
    Genetic variants as markers for use in diagnosis, prognosis and treatment of eosinophilia, asthma, and myocardial infarction 有权
    遗传变异作为标记用于诊断，预后和治疗嗜酸性粒细胞增多，哮喘和心肌梗塞

    公开(公告)号：US08367333B2

    公开(公告)日：2013-02-05

    申请号：US12636082

    申请日：2009-12-11

    申请人： Daniel Gudbjartsson ,  Unnur S. Bjornsdottir ,  Patrick Sulem

    发明人： Daniel Gudbjartsson ,  Unnur S. Bjornsdottir ,  Patrick Sulem

    IPC分类号： C12P19/34

    CPC分类号： C12Q1/6883 ,  A61B5/026 ,  A61B5/0402 ,  A61B5/4839 ,  A61B5/4884 ,  A61B6/503 ,  A61B6/504 ,  A61B8/0883 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/172 ,  C12Q2600/178 ,  G06F19/22 ,  Y02A90/26

    摘要： Polymorphic variants (e.g., certain alleles of polymorphic markers) that have been found to be associated with high blood eosinophil counts, conditions causative of eosinophilia (e.g., asthma, myocardial infarction), and/or hypertension are provided herein. Such polymorphic markers are useful for diagnostic purposes, such as in methods of determining a susceptibility, and for prognostic purposes, including methods of predicting prognosis and methods of assessing an individual for probability of a response to a therapeutic agent, as further described herein. Further applications utilize the polymorphic markers of the invention include, screening methods and genotyping methods. The invention furthermore provides related kits, computer-readable medium, and apparatus.

    摘要翻译： 已经发现已经发现与高血嗜酸性粒细胞计数相关的多形性变体（例如多态性标记的某些等位基因），嗜酸性粒细胞增多症（例如哮喘，心肌梗塞）和/或高血压引起的病症。 这样的多态性标记物可用于诊断目的，例如在确定易感性的方法中，以及用于预后目的，包括预测预后的方法和评估个体对治疗剂的应答概率的方法，如本文进一步描述的。 其他应用利用本发明的多态性标记包括筛选方法和基因分型方法。 本发明还提供了相关的试剂盒，计算机可读介质和装置。

    Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
    58.
    发明申请
    Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment 审中-公开
    心肌梗死，中风和PAOD的易感基因; 治疗方法

    公开(公告)号：US20100216863A1

    公开(公告)日：2010-08-26

    申请号：US11913807

    申请日：2006-03-30

    申请人： Anna Helgadottir ,  Hákon Hákonarson ,  Jeffrey R. Gulcher ,  Mark E. Gurney

    发明人： Anna Helgadottir ,  Hákon Hákonarson ,  Jeffrey R. Gulcher ,  Mark E. Gurney

    IPC分类号： A61K31/7088 ,  C12Q1/68 ,  A61K31/7105 ,  A61P9/10

    CPC分类号： A61K31/225 ,  A61K31/366 ,  A61K31/401 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/172 ,  G01N2800/324

    摘要： Polymorphisms in the FLAP and LTA4H gene are shown by genetic association analysis to be susceptibility markers for myocardial infarction (MI) and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described. The invention also provides methods of prophylaxis therapy for MI in human subjects having a race including black African ancestry by administering to the subject a composition comprising a therapeutically effective amount of MI therapeutic agent that inhibits leukotriene synthesis in vivo. The invention also provides for compositions comprising a leukotriene synthesis inhibitor and a statin and methods of using these compositions to reduce C-reactive protein in a human subject at risk of MI, ACS, stroke and/or PAOD.

    摘要翻译： FLAP和LTA4H基因的多态性通过遗传关联分析显示为心肌梗死（MI）和ACS以及中风和PAOD的敏感性标志物。 描述了针对治疗和诊断应用的途径，用于鉴定那些处于发展中心，ACS，中风或PAOD风险的患者。 本发明还提供了通过向受试者施用包含治疗有效量的体内抑制白细胞三烯合成的MI治疗剂的组合物的组合，在具有包括黑非洲血统的种族的人类受试者中预防MI治疗的方法。 本发明还提供了包含白三烯合成抑制剂和他汀类的组合物以及使用这些组合物降低患有MI，ACS，中风和/或PAOD风险的人类受试者中的C-反应蛋白的方法。

    GENETIC SUSCEPTIBILITY VARIANTS ASSOCIATED WITH CARDIOVASCULAR DISEASE
    60.
    发明申请
    GENETIC SUSCEPTIBILITY VARIANTS ASSOCIATED WITH CARDIOVASCULAR DISEASE 有权
    与心脏病相关的遗传易感性变异

    公开(公告)号：US20100068705A1

    公开(公告)日：2010-03-18

    申请号：US12302538

    申请日：2008-02-21

    申请人： Anna Helgadottir ,  Gudmar Thorleifsson ,  Andrei Manolescu

    发明人： Anna Helgadottir ,  Gudmar Thorleifsson ,  Andrei Manolescu

    IPC分类号： C12Q1/68 ,  G06F19/00

    CPC分类号： C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/172 ,  Y02A90/26

    摘要： The invention relates to methods of diagnosing susceptibility to cardiovascular disease, including coronary artery disease. MI, abdominal aorta aneurysm, intracranial aneurysm restenosis and peripheral arterial disease, by assessing the presence or absence of alleles of certain polymorphic markers found to be associates with cardiovascular disease. The invention further relates to kits encompassing reagents for assessing such markers, and methods for assessing the probability of response to therapeutic agents and methods using such markers.

    摘要翻译： 本发明涉及诊断心血管疾病易感性的方法，包括冠状动脉疾病。 MI，腹主动脉动脉瘤，颅内动脉瘤再狭窄和外周动脉疾病，通过评估发现与心血管疾病相关联的某些多态性标记的等位基因的存在或不存在。 本发明还涉及包含用于评估这种标记的试剂的试剂盒，以及评估对治疗剂的应答可能性的方法和使用这种标记物的方法。